Related Experiment Video
Updated: Jun 5, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Factor Xa inhibitors for acute coronary syndromes
Viviana Brito1, Agustín Ciapponi, Joey Kwong
1Coronary Care Unit, Hospital de Clinicas, Universidad de Buenos Aires, Avenida Cordoba 2351 Piso Sala 1, Ciudad Autonoma Buenos Aires, Capital Federal, Argentina.
The Cochrane Database of Systematic Reviews
|January 21, 2011
Summary
New factor Xa inhibitors, like fondaparinux, show reduced mortality in acute coronary syndromes (ACS) compared to standard treatments. Fondaparinux also demonstrated a better safety profile, with less bleeding risk than enoxaparin.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Coagulation activation is key in acute coronary syndromes (ACS) pathogenesis.
- Unfractionated heparin (UFH) and low molecular weight heparins (LMWH) are standard treatments, but have limitations.
- Development of novel synthetic anticoagulants is ongoing.
Purpose of the Study:
- To assess the clinical effectiveness and safety of factor Xa inhibitors versus UFH or LMWH in ACS patients.
- To compare outcomes including mortality, myocardial infarction, and bleeding events.
Main Methods:
- Systematic review and meta-analysis of four randomized controlled trials (RCTs) involving 27,976 participants.
- Searched major databases (Cochrane, PubMed, EMBASE, LILACS) and congress proceedings.
- Analyzed data using risk ratios (RR) and 95% confidence intervals (CI).
Main Results:
- Fondaparinux, the sole factor Xa inhibitor studied, reduced all-cause mortality at 90-180 days (RR 0.89; 95% CI 0.81-0.97) versus enoxaparin.
- Fondaparinux showed significantly lower major and minor bleeding risk compared to enoxaparin (RR 0.63 and 0.34, respectively).
- No significant difference in bleeding risk was observed when comparing fondaparinux to UFH.
Conclusions:
- Factor Xa inhibitors, exemplified by fondaparinux, appear effective in reducing all-cause mortality in ACS patients.
- Fondaparinux offers a superior safety profile to enoxaparin, with decreased bleeding incidence.
- These findings support the use of factor Xa inhibitors as a therapeutic option in ACS management.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...